Literature DB >> 24449447

Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani.

Arpita Kulshrestha1, Vanila Sharma, Ruchi Singh, Poonam Salotra.   

Abstract

Leishmania donovani is the causative agent of anthroponotic visceral leishmaniasis in the Indian subcontinent. Oral miltefosine therapy has recently replaced antimonials in endemic areas. However, the drug is at risk of emergence of resistance due to unrestricted use, and, already, there are indications towards decline in treatment efficacy. Hence, understanding the mechanism of miltefosine resistance in the parasite is crucial. We employed genomic microarray analysis to compare the gene expression patterns of miltefosine-resistant and miltefosine-sensitive L. donovani. Three hundred eleven genes, representing ∼3.9% of the total Leishmania genome, belonging to various functional categories including metabolic pathways, transporters, and cellular components, were differentially expressed in miltefosine-resistant parasite. Results in the present study highlighted the probable mechanisms by which the parasite sustains miltefosine pressure including (1) compromised DNA replication/repair mechanism, (2) reduced protein synthesis and degradation, (3) altered energy utilization via increased lipid degradation, (4) increased ABC 1-mediated drug efflux, and (5) increased antioxidant defense mechanism via elevated trypanothione metabolism. The study provided the comprehensive insight into the underlying mechanism of miltefosine resistance in L. donovani that may be useful to design strategies to increase lifespan of this important oral antileishmanial drug.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24449447     DOI: 10.1007/s00436-014-3755-6

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  55 in total

1.  Prohibitin and RACK homologues are up-regulated in trypanosomes induced to undergo apoptosis and in naturally occurring terminally differentiated forms.

Authors:  S C Welburn; N B Murphy
Journal:  Cell Death Differ       Date:  1998-07       Impact factor: 15.828

2.  Structure of eukaryotic prefoldin and of its complexes with unfolded actin and the cytosolic chaperonin CCT.

Authors:  Jaime Martín-Benito; Jasminka Boskovic; Paulino Gómez-Puertas; José L Carrascosa; C Torrey Simons; Sally A Lewis; Francesca Bartolini; Nicholas J Cowan; José M Valpuesta
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

3.  Genomic organisation and expression of a differentially-regulated gene family from Leishmania major.

Authors:  H M Flinn; D F Smith
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

4.  Leishmania cell surface prohibitin: role in host-parasite interaction.

Authors:  Rohit Jain; Angana Ghoshal; Chitra Mandal; Chandrima Shaha
Journal:  Cell Microbiol       Date:  2009-11-02       Impact factor: 3.715

5.  Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites.

Authors:  Ruchi Singh; Dhiraj Kumar; Robert C Duncan; Hira L Nakhasi; Poonam Salotra
Journal:  Int J Antimicrob Agents       Date:  2010-04-27       Impact factor: 5.283

6.  Distinct overexpression of cytosolic and mitochondrial tryparedoxin peroxidases results in preferential detoxification of different oxidants in arsenite-resistant Leishmania amazonensis with and without DNA amplification.

Authors:  Yi-Chun Lin; Ju-Yu Hsu; Su-Chi Chiang; Sho Tone Lee
Journal:  Mol Biochem Parasitol       Date:  2005-04-07       Impact factor: 1.759

7.  Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania.

Authors:  H Lux; N Heise; T Klenner; D Hart; F R Opperdoes
Journal:  Mol Biochem Parasitol       Date:  2000-11       Impact factor: 1.759

8.  Proteomic analysis of miltefosine-resistant Leishmania reveals the possible involvement of eukaryotic initiation factor 4A (eIF4A).

Authors:  Gaganmeet Singh; Hemantkumar D Chavan; Chinmoy S Dey
Journal:  Int J Antimicrob Agents       Date:  2008-05-05       Impact factor: 5.283

Review 9.  Metabolism and functions of trypanothione in the Kinetoplastida.

Authors:  A H Fairlamb; A Cerami
Journal:  Annu Rev Microbiol       Date:  1992       Impact factor: 15.500

10.  RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study.

Authors:  Florence Le Calvez-Kelm; Javier Oliver; Francesca Damiola; Nathalie Forey; Nivonirina Robinot; Geoffroy Durand; Catherine Voegele; Maxime P Vallée; Graham Byrnes; Breast Cancer Family Registry; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Sean V Tavtigian; Fabienne Lesueur
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

View more
  16 in total

1.  Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.

Authors:  Maya Berg; Raquel García-Hernández; Bart Cuypers; Manu Vanaerschot; José I Manzano; José A Poveda; José A Ferragut; Santiago Castanys; Jean-Claude Dujardin; Francisco Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.

Authors:  Deepak Kumar Deep; Ruchi Singh; Arpita Kulshrestha; Saima Wajid; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

3.  In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.

Authors:  C D Shaw; J Lonchamp; T Downing; H Imamura; T M Freeman; J A Cotton; M Sanders; G Blackburn; J C Dujardin; S Rijal; B Khanal; C J R Illingworth; G H Coombs; K C Carter
Journal:  Mol Microbiol       Date:  2016-02-09       Impact factor: 3.501

4.  Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.

Authors:  Saumya Srivastava; Jyotsna Mishra; Anil Kumar Gupta; Amit Singh; Prem Shankar; Sarman Singh
Journal:  Parasit Vectors       Date:  2017-01-31       Impact factor: 3.876

5.  Identifying miltefosine-resistant key genes in protein-protein interactions network and experimental verification in Iranian Leishmania major.

Authors:  Niloofar Lari; Razieh Jalal; Zarrin Minuchehr; Majid Rajabian Noghondar
Journal:  Mol Biol Rep       Date:  2019-08-05       Impact factor: 2.316

Review 6.  Drug resistance in eukaryotic microorganisms.

Authors:  Alan H Fairlamb; Neil A R Gow; Keith R Matthews; Andrew P Waters
Journal:  Nat Microbiol       Date:  2016-06-24       Impact factor: 17.745

7.  Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.

Authors:  Annelies Mondelaers; Maria P Sanchez-Cañete; Sarah Hendrickx; Eline Eberhardt; Raquel Garcia-Hernandez; Laurence Lachaud; James Cotton; Mandy Sanders; Bart Cuypers; Hideo Imamura; Jean-Claude Dujardin; Peter Delputte; Paul Cos; Guy Caljon; Francisco Gamarro; Santiago Castanys; Louis Maes
Journal:  PLoS One       Date:  2016-04-28       Impact factor: 3.240

8.  Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.

Authors:  V Ramesh; Ruchi Singh; Kumar Avishek; Aditya Verma; Deepak Kumar Deep; Sandeep Verma; Poonam Salotra
Journal:  PLoS Negl Trop Dis       Date:  2015-10-22

Review 9.  Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.

Authors:  Alicia Ponte-Sucre; Francisco Gamarro; Jean-Claude Dujardin; Michael P Barrett; Rogelio López-Vélez; Raquel García-Hernández; Andrew W Pountain; Roy Mwenechanya; Barbara Papadopoulou
Journal:  PLoS Negl Trop Dis       Date:  2017-12-14

10.  Modeling and simulation study to identify threonine synthase as possible drug target in Leishmania major.

Authors:  Rohan J Meshram; Kamini T Bagul; Snehal U Aouti; Akshay M Shirsath; Harleen Duggal; Rajesh N Gacche
Journal:  Mol Divers       Date:  2020-07-31       Impact factor: 3.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.